Neuroprotective mechanisms of SMTP-7 in cerebral infarction model in mice

被引:27
|
作者
Shibata, Keita [1 ]
Hashimoto, Terumasa [1 ]
Nobe, Koji [1 ]
Hasumi, Keiji [2 ]
Honda, Kazuo [1 ]
机构
[1] Showa Univ, Sch Pharm, Dept Pharmacol, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan
[2] Tokyo Univ Agr & Technol, Dept Appl Biol Sci, Fuchu, Tokyo 1838509, Japan
关键词
Antioxidant effects; Embolic cerebral infarction; Ischemia; ROS; SMTP-7; LIPID-PEROXIDATION; BRAIN; IRON;
D O I
10.1007/s00210-011-0642-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Reactive oxygen species (ROS) formation has been found to induce the brain damage following stroke-like events. The aim of the present study was to investigate the effect of Stachybotrys microspora triprenyl phenol-7 (SMTP-7) on the generation of ROS in ischemia-induced cerebral infarction model and in vitro lipid peroxidation. We used immunohistochemistry and real-time reverse-transcription PCR for ex vivo evaluation and thiobarbituric acid-reactive substance reagent assay for in vitro evaluation. We demonstrated that SMTP-7 did not induce enhancement of 4-hydroxynonenal or neutrophil cytosolic factor 2 like t-PA administration at 3 h after ischemia ex vivo and reduce lipid peroxidation in vitro. This compound is the first low molecular weight compound with triplet activities of thrombolytic, anti-inflammatory, and antioxidant activities. We theorized that SMTP-7 is among the pharmacological agents that reduce ROS formation and have been found to limit the extent of brain damage following stroke-like events.
引用
收藏
页码:103 / 108
页数:6
相关论文
共 50 条
  • [11] SMTP-7, a novel anti-inflammatory thrombolytic, treats serious cardioembolic stroke in a monkey model
    Nishimura, N.
    Sawada, N.
    Hasegawa, K.
    Hasumi, K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 437 - 438
  • [12] Absolute configuration determination of SMTP-7 via microcrystal electron diffraction (MicroED)
    Wang, Bo
    Lin, Yiqing
    CHEMICAL COMMUNICATIONS, 2022, 58 (94) : 13071 - 13074
  • [13] Evaluation of the therapeutic effect of novel stroke drug SMTP-7 on embolic stroke in monkeys
    Suzuki, E.
    Kunikiyo, Y.
    Matsumoto, N.
    Sawada, H.
    Nishimura, N.
    Hasegawa, K.
    Hasumi, K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 694 - 694
  • [14] Activation of fibrinolysis by SMTP-7 and-8, novel staplabin analogs with a pseudosymmetric structure
    Hu, WM
    Ohyama, S
    Hasumi, K
    JOURNAL OF ANTIBIOTICS, 2000, 53 (03): : 241 - 247
  • [15] Mechanism of the action of SMTP-7, a novel small-molecule modulator of plasminogen activation
    Koyanagi, Keiji
    Narasaki, Ritsuko
    Yamamichi, Shingo
    Suzuki, Eriko
    Hasumi, Keiji
    BLOOD COAGULATION & FIBRINOLYSIS, 2014, 25 (04) : 316 - 321
  • [16] Neuroprotective effect of γ-glutamylethylamide (theanine) on cerebral infarction in mice
    Egashira, N
    Hayakawa, K
    Mishima, K
    Kimura, H
    Iwasaki, K
    Fujiwara, M
    NEUROSCIENCE LETTERS, 2004, 363 (01) : 58 - 61
  • [17] SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates
    Sawada, Hironobu
    Nishimura, Naoko
    Suzuki, Eriko
    Zhuang, Jie
    Hasegawa, Keiko
    Takamatsu, Hiroyuki
    Honda, Kazuo
    Hasumi, Keiji
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2014, 34 (02): : 235 - 241
  • [18] Soluble Epoxide Hydrolase as an Anti-inflammatory Target of the Thrombolytic Stroke Drug SMTP-7
    Matsumoto, Naoki
    Suzuki, Eriko
    Ishikawa, Makoto
    Shirafuji, Takumi
    Hasumi, Keiji
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (52) : 35826 - 35838
  • [19] Soluble Epoxide Hydrolase As An Anti-Inflammatory Target Of The Thrombolytic Stroke Drug Candidate Smtp-7
    Suzuki, Eriko
    Matsumoto, Naoki
    Shibata, Keita
    Hashimoto, Terumasa
    Honda, Kazuo
    Hasumi, Keiji
    BLOOD, 2013, 122 (21)
  • [20] Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys
    Suzuki, Eriko
    Nishimura, Naoko
    Yoshikawa, Tetsuya
    Kunikiyo, Yudai
    Hasegawa, Keiko
    Hasumi, Keiji
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2018, 6 (06):